Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

ABSTRACT:

Objectives

Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was to determine molecular markers and breakpoints predicting second-line treatment outcomes in M. tuberculosis patients treated with fourth-generation fluoroquinolones.

Methods

We analysed treatment outcome data in relation to the gyrA and gyrB sequences and MICs of ofloxacin, gatifloxacin and moxifloxacin for pretreatment M. tuberculosis isolates from 181 MDR-TB patients in Bangladesh whose isolates were susceptible to injectable drugs.

Results

The gyrA 90Val, 94Gly and 94Ala mutations were most frequent, with the highest re

SUBMITTER: Rigouts L 

PROVIDER: S-EPMC4710215 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature